Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021
February 19, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the fiscal year ended...
Y-mAbs Announces Pricing of Public Offering of Common Stock
February 17, 2021 19:14 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Proposed Public Offering of Common Stock
February 16, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Sale of Priority Review Voucher
December 28, 2020 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China
December 18, 2020 09:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe
December 18, 2020 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Pipeline Update
December 16, 2020 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO
December 09, 2020 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16
December 07, 2020 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...